文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.

作者信息

Even Marie-Paule, Young Katie, Winter Gerhard, Hook Sarah, Engert Julia

机构信息

Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University Munich, Munich, Germany.

School of Pharmacy, University of Otago, Dunedin, New Zealand.

出版信息

Eur J Pharm Biopharm. 2014 Jul;87(2):338-46. doi: 10.1016/j.ejpb.2014.02.014. Epub 2014 Mar 4.


DOI:10.1016/j.ejpb.2014.02.014
PMID:24607791
Abstract

Sustained release systems have become the focus of attention in vaccine delivery as they may reduce or prevent the need for repeated dosing. In this work, lipid implants were prepared by twin-screw extrusion and investigated as vaccine delivery systems in vivo. The lipid implants consisted of cholesterol, soybean lecithin, and Dynasan 114. Ovalbumin (OVA) was employed as a model antigen and Quil-A (QA) as an adjuvant. In addition, OVA and QA loaded liposomes were prepared by the lipid-film hydration method, freeze-dried and then added to the lipid matrix prior to extrusion. Implants were administered subcutaneously and the kinetics of antigen release as well as the overall immune response stimulated were analysed by measuring CD4(+) and CD8(+) T cell proliferation, OVA-specific IgG production as well as cytokine (IFN-γ and IL4) secretion. Vaccine release from the implants was completed by 14 days. Inclusion of adjuvant into the implants was required for the generation of cellular and humoral immune responses. Inclusion of liposomes into the implant did not enhance the resulting immune responses generated.

摘要

相似文献

[1]
In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.

Eur J Pharm Biopharm. 2014-7

[2]
Immunostimulatory lipid implants containing Quil-A and DC-cholesterol.

Int J Pharm. 2008-11-3

[3]
Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.

J Liposome Res. 2011-12-22

[4]
Impact of implant composition of twin-screw extruded lipid implants on the release behavior.

Int J Pharm. 2015-7-15

[5]
Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation.

J Drug Target. 2008-4

[6]
Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A.

Pharmazie. 2008-9

[7]
Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses.

J Control Release. 2012-11-8

[8]
Twin-screw extruded lipid implants containing TRP2 peptide for tumour therapy.

Eur J Pharm Biopharm. 2017-5

[9]
Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.

Eur J Pharm Biopharm. 2008-9

[10]
Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.

J Control Release. 2010-8-18

引用本文的文献

[1]
Twin-screw extrusion of sustained-release oral dosage forms and medical implants.

Drug Deliv Transl Res. 2018-12

[2]
Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?

Pharm Res. 2016-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索